Want to see COYA full AI Analyst Report?
COYA Stock Chart & Stats
$4.25
-$0.13(-2.97%)
At close: 4:00 PM EDT
$4.25
-$0.13(-2.97%)
Day’s Range― - ―
52-Week Range$3.71 - $7.75
Previous Close$4.25
Volume159.10K
Average Volume (3M)266.35K
Market Cap
$110.02M
Enterprise Value$94.04
Total Cash (Recent Filing)$43.18B
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.22
Next Earnings
Nov 11, 2026EPS Estimate
-0.35Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.07
Shares Outstanding23,457,850
10 Day Avg. Volume216,274
30 Day Avg. Volume266,345
Financial Highlights & Ratios
PEG Ratio-0.15
Price to Book (P/B)2.26
Price to Sales (P/S)12.21
P/FCF Ratio-9.04
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$15.75Price Target Upside270.59% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-1.36
Revenue Forecast (FY)$2.37M
Bulls Say, Bears Say
Bulls Say
Debt-free Balance SheetZero reported debt materially reduces financing-related default and interest risk, preserving strategic optionality. For a clinical-stage biotech, this lowers fixed obligations and helps management prioritize R&D and partnership deals over debt servicing, supporting multi-quarter program execution.
Regulatory And Clinical ProgressFast Track and IND acceptance for COYA 302 are structural de-risking events: they can speed development, facilitate regulatory dialogue, and increase partner interest. Sustained clinical progress (Phase 2 enrollment) supports a multi-indication development path that underpins long-term program value.
Differentiated Treg-focused PlatformA focused platform targeting regulatory T‑cell biology across ALS and FTD creates a potential competitive moat if mechanism translates clinically. A mechanism-based, multi-indication approach increases addressable markets and partner licensing appeal, supporting durable R&D leverage if trials validate biology.
Bears Say
Very Large Cash BurnSustained, very large negative operating cash flow creates continuous funding pressure and shortens runway absent material cost cuts or new financing. For a clinical-stage firm, this forces reliance on external capital and can constrain strategic options and program pacing over the next several quarters.
Extremely Weak ProfitabilityMassive operating losses and deeply negative margins show the business is not yet generating scalable returns from operations. This fundamental lack of profitability limits internal funding capacity, heightens dilution risk, and makes long-term viability contingent on successful clinical outcomes or partner monetization.
Ongoing Reliance On External Equity FundingFrequent equity financings and access programs signal ongoing capital dependence. Repeated issuance risks dilution and ties execution to capital markets; without clinical de‑risking, management must keep raising funds, which can erode shareholder value and limit long-term strategic flexibility.
Coya Therapeutics, Inc. News
COYA FAQ
What was Coya Therapeutics, Inc.’s price range in the past 12 months?
Coya Therapeutics, Inc. lowest stock price was $3.71 and its highest was $7.75 in the past 12 months.
What is Coya Therapeutics, Inc.’s market cap?
Coya Therapeutics, Inc.’s market cap is $110.02M.
When is Coya Therapeutics, Inc.’s upcoming earnings report date?
Coya Therapeutics, Inc.’s upcoming earnings report date is Nov 11, 2026 which is in 88 days.
How were Coya Therapeutics, Inc.’s earnings last quarter?
Coya Therapeutics, Inc. released its earnings results on Aug 11, 2026. The company reported -$0.28 earnings per share for the quarter, beating the consensus estimate of -$0.346 by $0.066.
Is Coya Therapeutics, Inc. overvalued?
According to Wall Street analysts Coya Therapeutics, Inc.’s price is currently Undervalued.
Does Coya Therapeutics, Inc. pay dividends?
Coya Therapeutics, Inc. does not currently pay dividends.
What is Coya Therapeutics, Inc.’s EPS estimate?
Coya Therapeutics, Inc.’s EPS estimate is -0.35.
How many shares outstanding does Coya Therapeutics, Inc. have?
Coya Therapeutics, Inc. has 23,457,850 shares outstanding.
What happened to Coya Therapeutics, Inc.’s price movement after its last earnings report?
Coya Therapeutics, Inc. reported an EPS of -$0.28 in its last earnings report, beating expectations of -$0.346. Following the earnings report the stock price went up 3.448%.
Which hedge fund is a major shareholder of Coya Therapeutics, Inc.?
Currently, no hedge funds are holding shares in COYA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Coya Therapeutics, Inc. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$15.75 (270.59% Upside)
$15.75 (270.59% Upside)
Blogger Sentiment
Bullish
COYA Sentiment 100%
Sector Average ―
Sector Average ―
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.3%
Last 30 Days ▼ 4.8%
Last 30 Days ▼ 4.8%
News Sentiment
Bullish
Bullish news 67%
Bearish news 33%
Bearish news 33%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-32.31%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
41.42%
Trailing 12-Months
Company Description
Coya Therapeutics, Inc.
Coya Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing innovative therapeutic agents that fine-tune the function of regulatory T cells (Tregs). Its therapeutic pipeline leverages diverse approaches, including biologics designed to enhance Treg activity, Treg-derived exosomes, and personalized autologous Treg cell therapies. Among its lead candidates is COYA 101, an autologous regulatory T-cell product that has successfully completed Phase 2a clinical trials for treating Amyotrophic Lateral Sclerosis (ALS). Moving towards Investigational New Drug (IND) applications are two key candidates: COYA 301 and COYA 302. COYA 301 is a Treg-enhancing biologic aimed at treating Frontotemporal Dementia. Meanwhile, COYA 302 is a dual-action biologic combination, suitable for subcutaneous or intravenous delivery, engineered to not only boost Treg function but also to diminish harmful T effector cell activity and activated macrophages in neurodegenerative and autoimmune disorders. Additionally, Coya has earlier-stage programs, including COYA 201, an allogeneic (off-the-shelf) Treg exosome candidate in preclinical development for a range of neurodegenerative, autoimmune, and metabolic conditions. Its pipeline also features COYA 206, an antigen-directed Treg-derived exosome product, currently in the discovery phase. Established in 2020, Coya Therapeutics maintains its headquarters in Houston, Texas.
COYA Stock 12 Month Forecast
Average Price Target
$15.75
▲(270.59% Upside)
Technical Analysis
Ownership Overview
4.42% Insiders
4.45% Mutual Funds
6.80% Other Institutional Investors
80.04% Public Companies and
Individual Investors